Patient characteristics
| Characteristics . | Standard-Arm (n = 237) . | GO-Arm (n = 232) . | P . |
|---|---|---|---|
| Age, median (range), y | 58.6 (20.9-78.4) | 57.5 (19.3-82.3) | .67 |
| Age group, y | .76 | ||
| 18-60 | 138 (58) | 136 (59) | |
| 61-70 | 61 (26) | 64 (28) | |
| >70 | 38 (16) | 32 (14) | |
| Sex | .23 | ||
| Female | 120 (51) | 131 (56) | |
| Male | 117 (49) | 101 (44) | |
| Type of AML | .64 | ||
| De novo AML | 215 (91) | 206 (89) | |
| Secondary AML | 16 (7) | 21 (9) | |
| Therapy-related AML | 5 (2) | 5 (2) | |
| Missing | 1 | 0 | |
| White blood cell count, median (range), × 109/L | 18.1 (0.7-295.8) | 16.8 (0.6-278.9) | .97 |
| Platelets, × 109/L | .59 | ||
| Median (range) | 75 (8-660) | 75 (7-404) | |
| Missing | 0 | 1 | |
| Hemoglobin, g/dL | .17 | ||
| Median (range) | 9.4 (4.3-19.3) | 9.1 (4.4-15) | |
| Missing | 1 | 0 | |
| Blasts in BM, %* | .75 | ||
| Median (range) | 70 (16-100) | 75 (0-100) | |
| Missing | 5 | 7 | |
| LDH, U/L | .28 | ||
| Median (range) | 440 (86-5650) | 421 (137-7371) | |
| Missing | 1 | 1 | |
| Cytogenetics | .65 | ||
| Normal karyotype | 192 (89) | 187 (86) | |
| Other karyotypes | 22 (10) | 30 (14) | |
| Complex karyotype | 1 (<1) | 1 (<1) | |
| Missing | 22 | 14 | |
| FLT3-ITD | .22 | ||
| FLT3-ITD negative | 197 (83) | 200 (87) | |
| FLT3-ITD low (allelic ratio < 0.5) | 15 (6) | 16 (7) | |
| FLT3-ITD high (allelic ratio ≥ 0.5) | 25 (11) | 14 (6) | |
| Missing | 0 | 2 | |
| DNMT3A | .06 | ||
| DNMT3A wild-type | 95 (58) | 77 (47) | |
| DNMT3A mutated | 68 (42) | 86 (53) | |
| Missing | 74 | 69 | |
| FLT3-TKD | .16 | ||
| FLT3-TKD wild-type | 213 (90) | 198 (85) | |
| FLT3-TKD mutated | 24 (10) | 34 (15) | |
| Missing | 0 | 0 |
| Characteristics . | Standard-Arm (n = 237) . | GO-Arm (n = 232) . | P . |
|---|---|---|---|
| Age, median (range), y | 58.6 (20.9-78.4) | 57.5 (19.3-82.3) | .67 |
| Age group, y | .76 | ||
| 18-60 | 138 (58) | 136 (59) | |
| 61-70 | 61 (26) | 64 (28) | |
| >70 | 38 (16) | 32 (14) | |
| Sex | .23 | ||
| Female | 120 (51) | 131 (56) | |
| Male | 117 (49) | 101 (44) | |
| Type of AML | .64 | ||
| De novo AML | 215 (91) | 206 (89) | |
| Secondary AML | 16 (7) | 21 (9) | |
| Therapy-related AML | 5 (2) | 5 (2) | |
| Missing | 1 | 0 | |
| White blood cell count, median (range), × 109/L | 18.1 (0.7-295.8) | 16.8 (0.6-278.9) | .97 |
| Platelets, × 109/L | .59 | ||
| Median (range) | 75 (8-660) | 75 (7-404) | |
| Missing | 0 | 1 | |
| Hemoglobin, g/dL | .17 | ||
| Median (range) | 9.4 (4.3-19.3) | 9.1 (4.4-15) | |
| Missing | 1 | 0 | |
| Blasts in BM, %* | .75 | ||
| Median (range) | 70 (16-100) | 75 (0-100) | |
| Missing | 5 | 7 | |
| LDH, U/L | .28 | ||
| Median (range) | 440 (86-5650) | 421 (137-7371) | |
| Missing | 1 | 1 | |
| Cytogenetics | .65 | ||
| Normal karyotype | 192 (89) | 187 (86) | |
| Other karyotypes | 22 (10) | 30 (14) | |
| Complex karyotype | 1 (<1) | 1 (<1) | |
| Missing | 22 | 14 | |
| FLT3-ITD | .22 | ||
| FLT3-ITD negative | 197 (83) | 200 (87) | |
| FLT3-ITD low (allelic ratio < 0.5) | 15 (6) | 16 (7) | |
| FLT3-ITD high (allelic ratio ≥ 0.5) | 25 (11) | 14 (6) | |
| Missing | 0 | 2 | |
| DNMT3A | .06 | ||
| DNMT3A wild-type | 95 (58) | 77 (47) | |
| DNMT3A mutated | 68 (42) | 86 (53) | |
| Missing | 74 | 69 | |
| FLT3-TKD | .16 | ||
| FLT3-TKD wild-type | 213 (90) | 198 (85) | |
| FLT3-TKD mutated | 24 (10) | 34 (15) | |
| Missing | 0 | 0 |
Unless otherwise noted, data are n (%).
LDH, lactate dehydrogenase; TKD, tyrosine kinase domain.
If BM blasts < 20%, diagnosis of AML was established based on extramedullary disease or PB blood blasts ≥ 20%.